KSQ Appoints Mahesh Karande to its Board of Directors
LEXINGTON, Mass.–(Enterprise WIRE)–KSQ Therapeutics, a medical-phase biotechnology organization building therapies to deal with cancer and autoimmune ailments using its proprietary, built-in discovery CRISPRomics® system, right now declared the appointment of Mahesh Karande, President and CEO of Omega Therapeutics, to the company’s board of administrators.
“Mahesh’s deep knowledge in firm main, item commercialization, fundraising, and deal-making are wonderful additions to the skillset we have assembled on our board,” claimed Qasim Rizvi, Chief Executive Officer of KSQ Therapeutics. “His insights and guidance will be a must have as we proceed to advance KSQ-4279 through scientific scientific studies and operate in the direction of bringing our engineered TIL (eTIL™) mobile remedy systems into the clinic.”
“KSQ’s system and science are amazing and have yielded a number of interesting and novel targets that supply substantial possibilities to support individuals with different cancers and strong tumors,” stated Karande. “I seem forward to doing work closely with the organization to improve the probable of its applications, which include KSQ-4279 and the eTIL mobile treatment franchise, and I am fired up to see in which the CRISPRomics platform can take us as we move into new and remarkable locations, including NK cells, Tregs and myeloid cells.”
Mahesh is the President and CEO of Omega Therapeutics (Nasdaq: OMGA), a medical-phase biotechnology enterprise pioneering Omega Epigenomic Controllers, a new class of programmable mRNA medications. At Omega, he has led the company’s advancement of their Epigenomic Programming system and the translation of novel science into a broad pipeline in oncology, regenerative medication, immunology, inflammatory problems, and crucial monogenic circumstances. In advance of Omega, he was CEO of Macrolide Pharma, exactly where he re-assessed the company’s main strategy and optimized a route forward for the maximum shareholder return. Mahesh previously held many leadership roles at Novartis Prescription drugs, most not long ago as a company-degree Vice President and US franchise Head main the oncology solid tumors business. He also served as President of Africa, President of Egypt and Regional Vice President of tactic and company progress for emerging markets, exactly where he oversaw the execution of extra than 50 partnership deals. He has led much more than 10 solution launches in the U.S. and throughout world wide marketplaces. Prior to coming into the pharmaceutical sector, Mahesh worked for the international administration consulting firm McKinsey.
Mahesh has an M.B.A. from the Wharton School, College of Pennsylvania. He is also a graduate of the Ga Institute of Technological know-how, exactly where he accomplished his M.S. in engineering, and the University of Bombay, exactly where he concluded undergraduate research in engineering.
About KSQ Therapeutics
KSQ Therapeutics is advancing a pipeline of tumor- and immune-concentrated drug candidates to treat cancer and autoimmune disease throughout various drug modalities, which includes focused therapies, adoptive mobile therapies, and immunotherapies. KSQ’s proprietary CRISPRomics® discovery engine permits genome-scale, in vivo validated, unbiased drug discovery throughout broad therapeutic locations. For much more facts, you should take a look at the firm’s site at www.ksqtx.com and comply with @ksq_tx on Twitter.